{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:40:35Z","timestamp":1794069635642,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ishibashi Foundation for the Promotion of Science"},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018289","name":"Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kurume University Branding Project"},{"name":"JSPS KAKENHI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background &amp; aims<\/jats:title>\n                <jats:p>Combination immunotherapy refers to the use of immune checkpoint inhibitors (ICI) and molecular-targeted agents (MTA), which have recently been approved for the treatment of advanced hepatocellular carcinoma (HCC). Owing to its relatively low antitumor effect (up to 30%), sequential therapy following ICIs treatment is required in patients with HCC. This study aimed to determine the impact of MTAs on the tumor immune microenvironment (TIME).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We established immune syngeneic orthotopic HCC mouse models using Hep-55.1C and Hep-53.4, and treated them with MTAs (lenvatinib, sorafenib, regorafenib, cabozantinib, and DC101 as anti-vascular endothelial growth factor receptor-2 antibodies, and AZD4547 as a fibroblast growth factor receptor (FGFR)-1\/2\/3\/4 inhibitor) for 2\u00a0weeks. Subsequently, alterations in the TIME caused by MTAs were evaluated using immunohistochemistry (antibodies for CD3, CD8, Foxp3, Granzyme B, Arginase-1, NK1.1, F4\/80, CD11c, PD-1, and PD-L1). We conducted RNA-seq analysis using lenvatinib- and AZD4547-treated tumors. To confirm the clinical relevance of these findings, we analyzed the transcriptome data of human HCC cells (MHCC-97H) treated with various concentrations of lenvatinib for 24\u00a0h using RNA-seq data from the Gene Expression Omnibus database.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The number of Foxp3- and F4\/80-positive cells in the TIME was decreased in many MTAs. Cabozantinib increased the numbers in NK1.1-, Granzyme B, and CD11c-positive cells. Lenvatinib and AZD4547 increased the number of CD8, Granzyme B, and PD-L1-positive cells. Gene ontology enrichment analysis revealed that lipid metabolism-related genes were downregulated by lenvatinib and AZD4547. In total, 161 genes downregulated by FGFR inhibition in rodent models overlapped with those downregulated by lenvatinib in human HCC cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, we showed that cabozantinib activated the innate immune system, and lenvatinib and AZD4547, which commonly inhibit FGFR signaling, altered TIME to a hot immune state by downregulating lipid metabolism-related genes. These findings support the therapeutic use of combination immunotherapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12072-023-10603-z","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T10:02:30Z","timestamp":1697882550000},"page":"610-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2383-5038","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-1335","authenticated-orcid":false,"given":"Hideki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sakaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsutaka","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"issue":"3","key":"10603_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209\u2013249","journal-title":"CA: Cancer J Clin"},{"issue":"8","key":"10603_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525\u2013543","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"10603_CR3","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.3390\/cancers13112786","volume":"13","author":"H Iwamoto","year":"2021","unstructured":"Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers (Basel). 2021;13(11):2786","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10603_CR4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41556-022-01002-x","volume":"24","author":"KC Kao","year":"2022","unstructured":"Kao KC, Vilbois S, Tsai CH, Ho PC. Metabolic communication in the tumour-immune microenvironment. Nat Cell Biol. 2022;24(11):1574\u20131583","journal-title":"Nat Cell Biol"},{"issue":"5","key":"10603_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773\u20131796","journal-title":"Hepatology"},{"issue":"7854","key":"10603_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u2013456","journal-title":"Nature"},{"key":"10603_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.003","journal-title":"J Hepatol"},{"key":"10603_CR8","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0102","author":"H Koga","year":"2023","unstructured":"Koga H, Iwamoto H, Suzuki H, Shimose S, Nakano M, Kawaguchi T. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Japanese perspective. Clin Mol Hepatol. 2023. https:\/\/doi.org\/10.3350\/cmh.2023.0102","journal-title":"Clin Mol Hepatol"},{"key":"10603_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000513","author":"R Dhanasekaran","year":"2023","unstructured":"Dhanasekaran R, Suzuki H, Lemaitre L, Kubota N, Hoshida Y. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision making. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000513","journal-title":"Hepatology"},{"issue":"5","key":"10603_CR10","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr","year":"2003","unstructured":"Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3","journal-title":"Genome Biol"},{"key":"10603_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102463","volume":"56","author":"X Hao","year":"2022","unstructured":"Hao X, Zheng Z, Liu H, Zhang Y, Kang J, Kong X, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56: 102463","journal-title":"Redox Biol"},{"key":"10603_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1196\/annals.1317.011","volume":"1070","author":"A Chorny","year":"2006","unstructured":"Chorny A, Gonzalez-Rey E, Ganea D, Delgado M. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. Ann NY Acad Sci. 2006;1070:190\u2013195","journal-title":"Ann NY Acad Sci"},{"issue":"6","key":"10603_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1189\/jlb.0605299","volume":"78","author":"M Delgado","year":"2005","unstructured":"Delgado M, Chorny A, Gonzalez-Rey E, Ganea D. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol. 2005;78(6):1327\u20131338","journal-title":"J Leukoc Biol"},{"issue":"22","key":"10603_CR14","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.1002\/cam4.4312","volume":"10","author":"J Zhu","year":"2021","unstructured":"Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, et al. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med. 2021;10(22):7977\u20137987","journal-title":"Cancer Med"},{"key":"10603_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000209","author":"T Yamada","year":"2023","unstructured":"Yamada T, Fujiwara N, Kubota N, Matsushita Y, Nakatsuka T, Kurosaki S, et al. Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma. Hepatol Commun. 2023. https:\/\/doi.org\/10.1097\/HC9.0000000000000209","journal-title":"Hepatol Commun"},{"issue":"1","key":"10603_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000520278","volume":"11","author":"G Cabibbo","year":"2022","unstructured":"Cabibbo G, Reig M, Celsa C, Torres F, Battaglia S, Enea M, et al. First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials. Liver Cancer. 2022;11(1):75\u201384","journal-title":"Liver Cancer"},{"issue":"7","key":"10603_CR17","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/hep4.1927","volume":"6","author":"R Sharma","year":"2022","unstructured":"Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, et al. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022;6(7):1776\u20131785","journal-title":"Hepatol Commun"},{"issue":"2","key":"10603_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000512781","volume":"10","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer. 2021;10(2):107\u2013114","journal-title":"Liver Cancer"},{"issue":"2","key":"10603_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21873\/cdp.10012","volume":"1","author":"T Kuzuya","year":"2021","unstructured":"Kuzuya T, Kawabe N, Hashimoto S, Miyahara R, Nakano T, Nakaoka K, et al. Initial experience of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in clinical practice. Cancer Diagn Progn. 2021;1(2):83\u201388","journal-title":"Cancer Diagn Progn"},{"issue":"2","key":"10603_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1464","volume":"5","author":"A Hiraoka","year":"2022","unstructured":"Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience. Cancer Rep (Hoboken). 2022;5(2): e1464","journal-title":"Cancer Rep (Hoboken)"},{"key":"10603_CR21","doi-asserted-by":"publisher","DOI":"10.1159\/000531316","author":"A Hiraoka","year":"2023","unstructured":"Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al. Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma -clinical results show importance of hepatic reserve function. Oncology. 2023. https:\/\/doi.org\/10.1159\/000531316","journal-title":"Oncology"},{"issue":"4","key":"10603_CR22","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/cancers12041010","volume":"12","author":"H Iwamoto","year":"2020","unstructured":"Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, et al. Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers (Basel). 2020;12(4):1010","journal-title":"Cancers (Basel)"},{"issue":"Pt 3","key":"10603_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. Semin Cancer Biol. 2022;86(Pt 3):251\u2013261","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10603_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","volume":"111","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Brekken RA. Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukoc Biol. 2022;111(6):1269\u20131286","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10603_CR25","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1038\/s41467-020-17914-x","volume":"11","author":"JH Im","year":"2020","unstructured":"Im JH, Buzzelli JN, Jones K, Franchini F, Gordon-Weeks A, Markelc B, et al. FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat Commun. 2020;11(1):4064","journal-title":"Nat Commun"},{"issue":"1","key":"10603_CR26","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/s41467-023-37807-z","volume":"14","author":"DJ Kim","year":"2023","unstructured":"Kim DJ, Anandh S, Null JL, Przanowski P, Bhatnagar S, Kumar P, et al. Priming a vascular-selective cytokine response permits CD8. Nat Commun. 2023;14(1):2122","journal-title":"Nat Commun"},{"issue":"1","key":"10603_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","volume":"22","author":"R Ruan","year":"2023","unstructured":"Ruan R, Li L, Li X, Huang C, Zhang Z, Zhong H, et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment. Mol Cancer. 2023;22(1):60","journal-title":"Mol Cancer"},{"issue":"2","key":"10603_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14(2): e0212513","journal-title":"PLoS ONE"},{"issue":"2","key":"10603_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, et al. Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res. 2022;82(2):292\u2013306","journal-title":"Cancer Res"},{"issue":"5","key":"10603_CR30","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;74(5):2544\u20132560","journal-title":"Hepatology"},{"issue":"3","key":"10603_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000358640","volume":"33","author":"L Liu","year":"2014","unstructured":"Liu L, Ye TH, Han YP, Song H, Zhang YK, Xia Y, et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem. 2014;33(3):633\u2013645","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"10603_CR32","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","volume":"7","author":"S Palakurthi","year":"2019","unstructured":"Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7(9):1457\u20131471","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10603_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10","journal-title":"J Hematol Oncol"},{"key":"10603_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328364","author":"X Zhewen","year":"2023","unstructured":"Zhewen X, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023. https:\/\/doi.org\/10.1136\/gutjnl-2022-328364","journal-title":"Gut"},{"key":"10603_CR35","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3389\/fimmu.2017.01949","volume":"8","author":"D Howie","year":"2017","unstructured":"Howie D, Ten Bokum A, Necula AS, Cobbold SP, Waldmann H. The role of lipid metabolism in T lymphocyte differentiation and survival. Front Immunol. 2017;8:1949","journal-title":"Front Immunol"},{"issue":"7","key":"10603_CR36","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","volume":"9","author":"H Nishikawa","year":"2021","unstructured":"Nishikawa H, Koyama S. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021;9(7):e002591","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10603_CR37","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","volume":"72","author":"Z Xiong","year":"2023","unstructured":"Xiong Z, Chan SL, Zhou J, Vong JSL, Kwong TT, Zeng X, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72(9):1758\u20131773","journal-title":"Gut"},{"issue":"7","key":"10603_CR38","first-page":"1382","volume":"9","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Liu H, Wang H, Lu M, Miao Y, Ding J, et al. Lenvatinib promotes antitumor immunity by enhancing the tumor infiltration and activation of NK cells. Am J Cancer Res. 2019;9(7):1382\u20131395","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10603_CR39","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.4049\/jimmunol.0804384","volume":"183","author":"S Scutera","year":"2009","unstructured":"Scutera S, Fraone T, Musso T, Cappello P, Rossi S, Pierobon D, et al. Survival and migration of human dendritic cells are regulated by an IFN-alpha-inducible Axl\/Gas6 pathway. J Immunol. 2009;183(5):3004\u20133013","journal-title":"J Immunol"},{"key":"10603_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.755433","volume":"11","author":"F Scirocchi","year":"2021","unstructured":"Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari IG, et al. Immunogenic cell death and immunomodulatory effects of cabozantinib. Front Oncol. 2021;11: 755433","journal-title":"Front Oncol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10603-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10603-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T19:11:09Z","timestamp":1712949069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10603-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10603"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10603-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takumi Kawaguchi received lecture fees from Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., and EA Pharma Co., Ltd. and a research grant from Eisai Co., Ltd. Yujin Hoshida owns stock in Alentis Therapeutics and Espervita Therapeutics and advises on Helio Genomics, Espertiva Therapeutics, and Roche Diagnostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study approval statement: all animal experiments were approved by the ethical committee of the Kurume University School of Medicine (Kurume, Japan) (ethical code:2021-049).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}